Prostate cancer remains the most commonly diagnosed cancer in men in the United States, with nearly 300,000 new cases expected by the end of 2024. According to the American Cancer Association, ...

A cancer diagnosis is scary. Some doctors say it’s time to rename low-grade prostate cancer to eliminate the alarming C-word. Cancer cells develop in nearly all prostates as men age, and most prostate ...

Half of men with low-risk prostate cancer remained free from progression or treatment 10 years after diagnosis when followed in a protocol-directed active surveillance program. At 10 years, 43% of ...

A recent study published in JAMA Oncology shows a newly uncovered benefit to maintaining a healthy diet: keeping low-grade prostate cancer low-grade. Upon diagnosis, pathologists assign prostate ...

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

Findings from a recent study challenge a push to reclassify low grade prostate cancer, Biopsy Gleason Grade Group 1, as “benign.” Anthony D’Amico, MD, PhD, chief of genitourinary radiation oncology at ...

Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume should also guide treatment. Biopsy results alone may not fully capture the ...

In a peer-reviewed study believed to be the first of its kind published, a research team led by Johns Hopkins Medicine provides scientific evidence that a healthy diet may reduce the chance of low ...

Men could benefit from fewer unnecessary treatments and reduced anxiety if their doctors stopped calling certain changes in the prostate “cancer,” according to prominent UC San Francisco prostate ...

A prostate cancer biomarker test that utilizes 17 genetic markers has demonstrated a high degree of accuracy in screening for serious cancer. The test also significantly reduced unnecessary biopsies ...

Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...